ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

iron isomaltoside 1000

Also written as “Iron isomaltoside 1000”, “Iron isomaltoside/ferric derisomaltose” and “Monofer”.

Its studies are mostly in Anemia, Iron-Deficiency · Inflammatory Bowel Diseases · Renal Insufficiency, Chronic · Iron Deficiencies · Postpartum Hemorrhage, led by 2 companies.

Drug pageIron isomaltoside 1000: every studyAll 80 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 13, 201730 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharmacosmosits history only292 open or runningphase 4since Jun 13, 2017Sep 27, 2007Apr 30, 2027phase 3 · NCT05179226
Sichuan Huiyu Pharmaceutical11 open or runningphase 1since Jul 27, 2026Jul 27, 2026none ahead

Also a collaborator on its studies: Boji Medical Technology, BioStata, ClinStar, Laboratory Corporation of America and ClinSmart.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sichuan Huiyu Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2026First study: phase 1 study in Anemia, Iron-DeficiencyFirst studyNCT07790562 · 88 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Sichuan Huiyu Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07790562Anemia, Iron-Deficiency · China1Active, not recruitingSep 29, 202688

How it is read

Names in the registry

  • “Iron isomaltoside 1000”, 6 entries
  • “Iron isomaltoside/ferric derisomaltose”, 5 entries
  • “Monofer”, 5 entries
  • “Ferric Derisomaltose”, 2 entries
  • “Iron Isomaltoside”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.